🇺🇸 FDA
Patent

US 10415037

Compositions and methods for silencing hepatitis B virus gene expression

granted A61KA61K31/713A61K47/18

Quick answer

US patent 10415037 (Compositions and methods for silencing hepatitis B virus gene expression) held by ARBUTUS BIOPHARMA CORPORATION expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ARBUTUS BIOPHARMA CORPORATION
Grant date
Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K31/713, A61K47/18, A61K47/24, A61K47/28